Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD of Zabedosertib in Healthy Men
NCT03054402Phase 1Completed
- Sponsor
- Bayer
- Start
- Feb 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pelvic inflammatory disease (PID) comparing Dose escalation/BAY1834845 with Placebo (2 arms). Primary endpoints: Frequency of treatment-emergent adverse events, Severity of treatment-emergent adverse events and 2 more. Started Feb 2017; status: completed.
02
Drugs
zabedosertib
03
Conditions
pelvic inflammatory disease (PID)
Beyond the preview
Go deeper on NCT03054402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03054402.